Corbus Pharmaceuticals Holdings, Inc. Payments to Acquire Investments
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Payments to Acquire Investments of $19.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $8.70M, a 50.64% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $10.73M, a 71.48% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $90.02M, a 700.84% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $17.84M, a 54.06% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. payments to acquire investments for fiscal 2025 was $163.09M, a 9.80% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. payments to acquire investments for fiscal 2024 was $180.80M, a 433.58% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. payments to acquire investments for fiscal 2023 was $33.88M, a 60.75% decline from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. payments to acquire investments for fiscal 2022 was $86.34M, a 1.06% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 3 month as first filed | Payments to Acquire Investments 6 month | Payments to Acquire Investments 6 month as first filed | Payments to Acquire Investments 9 month | Payments to Acquire Investments 9 month as first filed | Payments to Acquire Investments 12 month | Payments to Acquire Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $19.42M 10-Q · filed 2026-08-06 | $109.45M derived: sum of 3 quarters · filed 2026-08-06 | $127.29M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $10.73M 10-Q · filed 2026-05-12 | $100.75M derived: sum of 2 quarters · filed 2026-05-12 | $118.59M derived: sum of 3 quarters · filed 2026-05-12 | $136.21M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $90.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $107.86M derived: sum of 2 quarters · filed 2026-03-09 | $125.49M derived: sum of 3 quarters · filed 2026-08-06 | $163.09M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $17.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $35.46M derived: sum of 2 quarters · filed 2026-08-06 | $73.07M 10-Q · filed 2025-11-12 | $84.31M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $17.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $55.23M 10-Q · filed 2026-08-06 | $66.47M derived: sum of 3 quarters · filed 2026-08-06 | $105.31M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $37.60M 10-Q · filed 2026-05-12 | $48.85M derived: sum of 2 quarters · filed 2026-05-12 | $87.68M derived: sum of 3 quarters · filed 2026-05-12 | $112.51M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $11.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $50.08M derived: sum of 2 quarters · filed 2026-03-09 | $74.91M derived: sum of 3 quarters · filed 2026-03-09 | $180.80M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $38.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $63.66M derived: sum of 2 quarters · filed 2025-11-12 | $169.56M 10-Q · filed 2025-11-12 | $172.89M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $24.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $130.72M 10-Q · filed 2025-08-05 | $134.05M derived: sum of 3 quarters · filed 2025-08-05 | $140.68M derived: sum of 4 quarters · filed 2025-08-05 | ||||
| 2024-03-31 | $105.90M 10-Q · filed 2025-05-06 | $105.90M 10-Q · filed 2024-05-07 | $109.23M derived: sum of 2 quarters · filed 2025-05-06 | $115.85M derived: sum of 3 quarters · filed 2025-05-06 | $126.47M derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $9.96M derived: sum of 2 quarters · filed 2025-03-11 | $20.58M derived: sum of 3 quarters · filed 2025-03-11 | $33.88M 10-K · filed 2025-03-11 | $33.88M 10-K · filed 2024-03-12 | |||
| 2023-09-30 | $6.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $17.25M derived: sum of 2 quarters · filed 2024-11-07 | $30.56M 10-Q · filed 2024-11-07 | $30.56M 10-Q · filed 2023-11-07 | $28.16M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | $10.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $23.93M 10-Q · filed 2024-08-06 | $23.93M 10-Q · filed 2023-08-08 | $21.53M derived: sum of 3 quarters · filed 2024-08-06 | $43.91M derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | $13.31M 10-Q · filed 2024-05-07 | $10.91M derived: sum of 2 quarters · filed 2024-05-07 | $33.28M derived: sum of 3 quarters · filed 2024-05-07 | $93.18M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $19.98M derived: sum of 2 quarters · filed 2024-03-12 | $79.87M derived: sum of 3 quarters · filed 2024-03-12 | $86.34M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $22.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $82.27M derived: sum of 2 quarters · filed 2023-11-07 | $88.74M 10-Q · filed 2023-11-07 | $98.74M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $59.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $66.37M 10-Q · filed 2023-08-08 | $76.37M derived: sum of 3 quarters · filed 2023-08-08 | $83.10M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $6.47M 10-Q · filed 2023-05-09 | $16.47M derived: sum of 2 quarters · filed 2023-05-09 | $23.21M derived: sum of 3 quarters · filed 2023-05-09 | $36.31M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $16.74M derived: sum of 2 quarters · filed 2023-03-07 | $29.84M derived: sum of 3 quarters · filed 2023-03-07 | $87.27M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $6.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $19.84M derived: sum of 2 quarters · filed 2022-11-08 | $77.27M 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | $13.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $70.53M 10-Q · filed 2022-08-09 | ||||||
| 2021-03-31 | $57.43M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |